Clinical trial
Ropivacaine Use in Interscalene Block; What is the Minimal Effective Analgesic Concentration (MEAC 90)
NCT04833296 is registered in ClinicalTrials.gov with Healthpoint Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Ropivacaine Use in Interscalene Block; What is the Minimal Effective Analgesic Concentration (MEAC 90)
- Lead sponsor
- Healthpoint Hospital
- Phase
- Phase 4
- Overall status
- Unknown status
- Start date
- May 1, 2021
- Completion date
- September 30, 2021
- Enrollment
- 45 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.